Outlook Therapeutics (OTLK) EBITDA: 2015-2020
Historic EBITDA for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$10.0 million.
- Outlook Therapeutics' EBITDA rose 21.10% to -$10.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$36.8 million, marking a year-over-year decrease of 1.49%. This contributed to the annual value of -$71.7 million for FY2024, which is 34.97% down from last year.
- Latest data reveals that Outlook Therapeutics reported EBITDA of -$10.0 million as of Q3 2020, which was up 15.70% from -$11.9 million recorded in Q2 2020.
- Over the past 5 years, Outlook Therapeutics' EBITDA peaked at -$2.9 million during Q3 2017, and registered a low of -$22.0 million during Q2 2016.
- For the 3-year period, Outlook Therapeutics' EBITDA averaged around -$9.1 million, with its median value being -$8.2 million (2019).
- Per our database at Business Quant, Outlook Therapeutics' EBITDA soared by 82.13% in 2017 and then slumped by 326.49% in 2018.
- Quarterly analysis of 5 years shows Outlook Therapeutics' EBITDA stood at -$17.8 million in 2016, then soared by 82.13% to -$3.2 million in 2017, then slumped by 222.58% to -$10.3 million in 2018, then increased by 20.21% to -$8.2 million in 2019, then climbed by 21.10% to -$10.0 million in 2020.
- Its EBITDA was -$10.0 million in Q3 2020, compared to -$11.9 million in Q2 2020 and -$6.8 million in Q1 2020.